Trial reportMultiple sclerosis (Houndmills, Basingstoke, England)2022
MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis.
Trial report in Multiple sclerosis (Houndmills, Basingstoke, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Progressive motor impairment from intracerebral critical demyelinating lesions.Journal of neurology · 2026Article
- Dissecting definitions of disability accrual in relapsing multiple sclerosis-Have we reached standardization yet?Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Observational
- Exploring factors driving the evolution of chronic lesions in multiple sclerosis using machine learning.European radiology · 2025Article
- Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis.Annals of clinical and translational neurology · 2025Article
- The Role of MRI Lesions in Identifying Secondary Progressive Multiple Sclerosis: A Comprehensive Review.Journal of clinical medicine · 2025Review
- A systematic literature review of the association between global brain atrophy and the Expanded Disability Status Scale score in people with multiple sclerosis.Therapeutic advances in neurological disorders · 2025Review
- Deep learning-driven MRI for accurate brain volumetry in murine models of neurodegenerative diseases.Frontiers in neuroscience · 2025Article
- Predicting multiple sclerosis prognosis using AI and machine learning: integrating clinical, immunological, and radiological variables.Frontiers in neurology · 2025Article
- Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MS.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Review
- Oligoclonal Band Status and Features of Radiological and Clinical Findings in Patients with Multiple Sclerosis in Lithuania.Medicina (Kaunas, Lithuania) · 2023Article
- Diagnosis and treatment of progressive multiple sclerosis: A position paper.European journal of neurology · 2023Review
- Neurodegeneration in multiple sclerosis.WIREs mechanisms of disease · 2023Review
- Processing speed and memory test performance are associated with different brain region volumes in Veterans and others with progressive multiple sclerosis.Frontiers in neurology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMagnetic resonance imaging (MRI) of brain volume measures are widely used outcomes in secondary progressive multiple sclerosis (SPMS), but it is unclear whether they are associated with physical and cognitive disability.
objectiveTo investigate the association between MRI outcomes and physical and cognitive disability worsening in people with SPMS.
methodsWe used data from ASCEND, a large randomized controlled trial (
resultsWe found no association between MRI measures and EDSS or SDMT worsening. T25FW worsening at 48 and 96 weeks, and NHPT worsening at 96 weeks were associated with cumulative new or newly enlarging T2 lesions at 96 weeks. NHPT worsening at 48 and 96 weeks was associated with normalized brain volume loss at 48 weeks, but not with other MRI outcomes.
conclusionThe association of standard MRI outcomes and disability was noticeably weak and inconsistent over 2 years of follow-up. These MRI outcomes may not be useful surrogates of disability measures in SPMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.